TRexBio Prices $117 Million IPO at $14 Per Share
TRex Bio (TRXB), a clinical-stage biotechnology company, has priced its initial public offering (IPO) at $14 per share. The firm plans to raise approximately $116.7 million in gross proceeds by issuing 8.33 million shares. The stock is expected to begin trading on the Nasdaq Global Market. The IPO reflects investor interest in TRex Bio's focus on developing immunoregulatory medicines, which aim to modulate immune responses for therapeutic purposes. As a clinical-stage company, it has not yet commercialized any products but is advancing its pipeline through various stages of development.
Topics: biotechnology capital raising ipo